Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT06416007 Not yet recruiting - Cancer Clinical Trials

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

NCT ID: NCT06415201 Recruiting - Cancer Clinical Trials

Interactive AI-based Mental Health Service for the Patients With Cancer

Start date: March 1, 2024
Phase:
Study type: Observational

The aims of this study are developments of mental health care services for cancer patients based on interactive artificial intelligence. To do these things, survey of unmet medical needs and data collection of clinical interviews will be done, and newly developed assessment and intervention scenarios will be simulated to cancer patients group.

NCT ID: NCT06414304 Recruiting - Cancer Clinical Trials

Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy

BLOOMSI
Start date: June 1, 2022
Phase:
Study type: Observational

Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Microsatellite instability or mismatch repair deficiency occurs in 20% of CRC, and is predominantly found in non-metastatic tumors. The success of the CheckMate 142 and KEYNOTE-177 clinical trials has shifted the treatment paradigm of the MSI/dMMR CRC, which has led to the adoption of immune checkpoint inhibitors (ICI) by international treatment standards. However, despite the encouraging effects of ICI, up to 30% of patients are resistant to treatment and exhibit rapid disease progression shortly after starting ICI. On the other hand, around 30% of patients treated with ICI demonstrate prolonged responses to the treatment with a duration of response of over 40 months. Furthermore, for ~10% of patients, treatment with ICI results in pseudo-progression - a phenomenon of a short-term increase followed by the decrease of the tumor volume. Currently, the mechanisms and biomarkers associated with the response or resistance to ICI in MSI-positive CRC are largely unknown. Select studies suggest that BRAF mutations (specifically, BRAF p.V600E) might negatively affect the patients' progression-free survival following ICI, however, these data are premature. The primary hypothesis is that the clonal heterogeneity and the evolution of MSI status of MSI-positive CRC will play a role in the development of ICI treatment resistance. The primary objective of the study is to investigate the dynamics of MSI status in serial liquid biopsy samples from patients with MSI-positive tumors receiving ICI.

NCT ID: NCT06413628 Completed - Cancer Clinical Trials

Efficiency of Different Treatment Modalities on Radiation Induced Trismus for Maxillofacial Patients

Start date: April 11, 2022
Phase: N/A
Study type: Interventional

Aim: to compare different treatment modalities for radiation induced trismus for maxillofacial patients methods:45 participants (20 females and 25 males) with trismus and pain following head and neck cancer and underwent radiation therapy were enrolled in this study . patients were divided into three groups : group1 received threaded tapered screw appliance therapy, patients in group II received low-level laser therapy and patients in group III received low-level laser therapy in addition to threaded tapered screw appliance therapy.

NCT ID: NCT06412029 Not yet recruiting - Cancer Clinical Trials

Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practices

HRSN
Start date: August 2024
Phase:
Study type: Observational

This study evaluates health related social needs screening processes in community oncology clinics.

NCT ID: NCT06409481 Not yet recruiting - Cancer Clinical Trials

Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)

PARCA
Start date: June 1, 2024
Phase:
Study type: Observational

The aim of this observational study is to explore and analyze reports of cardiac or vascular adverse events linked to the administration of antineoplastic agents among patients diagnosed with tumors represented by advanced non-small cell lung cancer. The study leverages pharmacovigilance databases such as the World Health Organization (WHO) database (VigiBase), FDA Adverse Event Reporting System (FAERS), and others to gather individual safety case reports for analysis.

NCT ID: NCT06409065 Recruiting - Cancer Clinical Trials

Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers

Start date: January 9, 2024
Phase: N/A
Study type: Interventional

The goal of this behavioral research study is to learn about the effects of two different supportive care programs on patients' and their family caregivers' psychological wellbeing and overall quality of life.

NCT ID: NCT06403436 Recruiting - Cancer Clinical Trials

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

TT-CSP-001
Start date: November 7, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors.

NCT ID: NCT06402812 Completed - Cancer Clinical Trials

The Perceived Mismatch Between Dose Recommendations of PKI's and the Clinical Practice

Start date: February 6, 2024
Phase:
Study type: Observational

A qualitative research study will be conducted using semi-structured interviews. The target population includes regulators involved in the registration of PKIs and healthcare professionals who use PKIs in clinical practice. Participants will be recruited until a rich understanding of the subject is reached.

NCT ID: NCT06393764 Not yet recruiting - Cancer Clinical Trials

Cancer-related Venous Thromboembolic Disease - Cohort Study

CAPE
Start date: June 2024
Phase:
Study type: Observational

Venous thromboembolic disease (VTE) is a common (1/1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)). In cancer patients, the risk of developing VTE is high and constitutes a negative prognostic factor for cancer; the risk of bleeding is also increased. The study of VTE in the context of cancer is a major challenge, given the frequency of the association, the heterogeneity of the situations, the risk factors involved and the therapeutic issues in both curative and primary prevention; in this field, many uncertainties remain, justifying a study focused on the association of VTE and cancer.